DraxImage files for approval for brachytherapy implant

Radiopharmaceutical firm DraxImage has filed for clearance of its palladium-103 brachytherapy implant with the Food and Drug Administration and the Nuclear Regulatory Commission. Filings with Canadian regulatory authorities will follow shortly for the agent, which is designed for prostate cancer treatment, according to the Mississauga, Ontario-based vendor.

Palladium-103 BrachySeed will complement the firm's existing BrachySeed I-125 agent, according to Dr. Martin Barkin, president and CEO of DraxImage parent Draxis Health. The company anticipates that BrachySeed Pd-103 will become commercially available later this year, and will be distributed by Cytogen in the U.S. market. Cytogen already distributes BrachySeed I-125.

By AuntMinnie.com staff writers
April 27, 2001

Related Reading

DraxImage licenses Infecton Agent, March 15, 2001

DraxImage posts mixed Q3 results, November 8, 2000

Draxis gets Canadian OK for BrachySeed, October 10, 2000

DraxImage gets NRC approval for BrachySeed, September 22, 2000

Draxis signs brachytherapy seed agreement with Cytogen, September 14, 2000

Copyright © 2001 AuntMinnie.com

Page 1 of 436
Next Page